Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algocur is a nutraceutical supplement developed by Omeopiacenza (Pharmextracta) that utilizes a curcumin phytosome formulation (Meriva). This delivery system complexes curcumin with phosphatidylcholine to significantly enhance its oral bioavailability compared to standard curcumin extracts. Curcumin, the primary active constituent, exerts potent anti-inflammatory and antioxidant effects by modulating multiple molecular targets, including the inhibition of nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), and various pro-inflammatory cytokines such as TNF-α and IL-6. Algocur is primarily marketed in Italy as a supportive treatment for inflammatory conditions, pain management, and as an adjuvant in oncology to mitigate treatment-related side effects and support overall health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Algocur.